%0 Journal Article
%T Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy.
%A Rehman M
%A Qaiser A
%A Khan HS
%A Manzoor S
%A Ashraf J
%J Clin Exp Med
%V 24
%N 1
%D 2024 Aug 6
%M 39105978
%F 5.057
%R 10.1007/s10238-024-01442-9
%X CAR T-cell therapy is a promising immunotherapy, providing successful results for cancer patients who are unresponsive to standard and traditional therapeutic approaches. However, there are limiting factors which create a hurdle in the therapy performing its role optimally. CAR T cells get exhausted, produce active antitumor responses, and might even produce toxic reactions. Specifically, in the case of solid tumors, chimeric antigen receptor T (CAR-T) cells fail to produce the desired outcomes. Then, the need to use supplementary agents such as immune system modifying immunomodulatory agents comes into play. A series of the literature was studied to evaluate the role of immunomodulators including a phytochemical, Food and Drug Administration (FDA)-approved targeted drugs, and ILs in support of their achievements in boosting the efficiency of CAR-T cell therapy. Some of the most promising out of them are reported in this article. It is expected that by using the right combinations of immunotherapy, immunomodulators, and traditional cancer treatments, the best possible cancer defying results may be produced in the future.